Skip to main content

Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument


Citation:

See Citation Policies for referencing Mol*, RCSB PDB, PDB structures, and Computed Structure Models.